Solubility based Biowaiver [Dissolution / BCS / IVIVC]

posted by The Outlaw Torn – Europe, 2018-10-02 11:51 (2023 d 10:37 ago) – Posting: # 19361
Views: 5,983

what I guess I should have clarified is that the reason we are trying to use this justification is because the lower strength is not proportional in terms of excipients.


❝ ❝ The advise was given by an "external clinical expert".


Where is the difference coming from?

Is the API less than 5% of the total weight of the tablet?

Take a look at the General biowaiver criteria on page 12 of the guideline. If you don't meet the conditions stated in c), you'll need to conduct a BE study at the lower strength too.

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,654 registered users;
54 visitors (0 registered, 54 guests [including 7 identified bots]).
Forum time: 22:29 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5